NCT04680988View on ClinicalTrials.gov

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

194

Participants

Timeline

Start Date

April 5, 2021

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions

Recurrent or Metastatic Cervical Cancer

Interventions

DRUG

SHR-1210

SHR-1210 intravenously every 3 weeks

DRUG

SHR-1020

SHR-1020 Orally once daily

DRUG

Physician's choice chemotherapy

Investigators will declare one of the following regimens:Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection

Trial Locations (1)

200000

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04680988 - A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer | Biotech Hunter | Biotech Hunter